Loading...
XJPX
7459
Market cap3.82bUSD
Oct 09, Last price  
2,953.50JPY
1D
0.15%
1Q
12.04%
Jan 2017
60.26%
Name

Medipal Holdings Corp

Chart & performance

D1W1MN
XJPX:7459 chart
P/E
14.21
P/S
0.16
EPS
207.79
Div yield, %
2.17%
Shrs. gr., 5y
-1.60%
Rev. gr., 5y
3.52%
Revenues
3.82t
+3.98%
2,166,762,000,0002,254,936,000,0002,463,569,000,0002,546,029,000,0002,662,821,000,0002,750,233,000,0002,810,959,000,0002,947,798,000,0002,872,905,000,0003,028,187,000,0003,064,041,000,0003,146,341,000,0003,181,935,000,0003,253,122,000,0003,211,173,000,0003,290,921,000,0003,360,008,000,0003,558,732,000,0003,671,328,000,0003,817,354,000,000
Net income
42.54b
+5.60%
19,105,000,00027,794,000,00012,510,000,0001,958,000,0001,704,000,00011,650,000,00018,655,000,00025,485,000,00023,687,000,00030,771,000,00029,012,000,00034,780,000,00034,359,000,00037,969,000,00023,927,000,00029,424,000,00038,806,000,00041,475,000,00040,280,000,00042,535,000,000
CFO
46.55b
-23.13%
19,836,000,00023,963,000,00023,371,000,00013,994,000,00049,473,000,000-1,989,000,00061,769,000,000-73,000,00080,465,000,00021,985,000,00047,954,000,00063,558,000,00063,716,000,00056,917,000,00034,448,000,00061,216,000,00016,146,000,00061,843,000,00060,559,000,00046,552,000,000
Dividend
Mar 30, 202744 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Medipal Holdings Corporation, a Tokyo-based Japanese company founded in 1898, primarily operates as a wholesaler of prescription pharmaceuticals throughout Japan. Beyond its core drug distribution, the company also sources and supplies a comprehensive range of healthcare-related products, including medical equipment, materials, and clinical diagnostic reagents, used from the earliest pre-symptomatic stages through treatment. Its services extend to offering post-marketing surveillance (PMS) to pharmaceutical manufacturers and investing in the development of orphan drugs. Medipal's extensive wholesale activities also encompass a diverse array of other goods, such as cosmetics, daily necessities, over-the-counter medications, and animal health products for companion animals. Furthermore, it provides raw materials for food processing in agriculture, fisheries, and livestock sectors, along with livestock feed additives, various seasonings, veterinary medical equipment, packaging materials, and industrial chemicals. In addition to its product distribution, Medipal delivers a suite of specialized services: conducting contract-based epidemiological and clinical studies, developing computerized medical supply and master product databases for healthcare facilities, and offering solutions for health insurance claims review, medical coding, outsourcing, and remote educational programs. Its operations further include managing life and non-life insurance agencies, providing cleaning services, overseeing distribution center logistics, offering commissioned delivery and staffing solutions, and developing and managing services for Class A health dispensing pharmacies. Medipal serves a broad client base, including hospitals, clinics, dispensing pharmacies, various retail outlets like drugstores, home centers, convenience stores, supermarkets, and discount stores, as well as animal hospitals, livestock and fishery businesses, and processed food manufacturers. The company was previously known as Mediceo Paltac Holdings Co., Ltd. before adopting its current name in October 2009.

Key people

Shuichi Watanabe
President, Chief Executive Officer, Representative Director · since 2022
Hiroshi Yarimizu
Senior Managing Executive Officer, Deputy Chief Director of Administration, Director of Finance and Accounting · since 2024
Shinjiro Watanabe
President of Subsidiary, Director · since 2021
Senior Managing Director, Chief Director of Business Development · since 2022
Managing Director, Chief Director of Administration · since 2018
Tetsuya Shoji
Senior Executive Officer, Chief Director of System · since 2025
Masahiro Fujimaki
Executive Officer · since 2025
Tadashi Hagiwara
Executive Officer, Deputy Chief Director of Administration · since 2025
Yoshitaka Ichiyanagi
Executive Officer, President of Subsidiary · since 2021
Takeshi Kumakura
Executive Officer, Chief Director of Data Insight, Director of Presus Business Promotion, President of Subsidiary · since 2025
Yasuhiko Sugimori
Executive Officer, Deputy Chief Director of Main Business Development Unit, Director of Business Development · since 2024
Ryo Ukita
Executive Officer, Director in charge of Business Investment Unit in Main Business Development Unit · since 2024
Yasuhiro Chofuku
Vice President, Chairman of Subsidiary, Representative Director · since 2025
Kuniaki Imagawa
President of Subsidiary, Director · since 2022
Hidemitsu Wakita
Director · since 2025
President of Subsidiary, Director · since 2023
Independent Director · since 2017
Hiroshi Iwamoto
Independent Director · since 2021
Mitsuko Kagami
Independent Director · since 2014
Kuniko Shoji
Independent Director · since 2018
IPO date
Sep 14, 1995
Employees
12,795
Domiciled in
JP
Incorporated in
JP
Headquarters & legal address
京橋三丁目1番1号
東京都 中央区 104-8461
JP
Address
3-1-1, Kyobashi
Chuo-ku Tokyo 104-8461
JP
Other language
MEDIPAL HOLDINGS CORPORATION

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT